ABVC BIOPHARMA INC (ABVC) Fundamental Analysis & Valuation

NASDAQ:ABVC • US00091F3047

1.42 USD
0 (0%)
Last: Mar 4, 2026, 12:55 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ABVC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ABVC. ABVC was compared to 520 industry peers in the Biotechnology industry. ABVC may be in some trouble as it scores bad on both profitability and health. ABVC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. ABVC Profitability Analysis

1.1 Basic Checks

  • ABVC had negative earnings in the past year.
  • ABVC had a negative operating cash flow in the past year.
  • In the past 5 years ABVC always reported negative net income.
  • ABVC had a negative operating cash flow in each of the past 5 years.
ABVC Yearly Net Income VS EBIT VS OCF VS FCFABVC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -19.44%, ABVC is in the better half of the industry, outperforming 75.96% of the companies in the same industry.
  • ABVC has a Return On Equity of -34.14%. This is in the better half of the industry: ABVC outperforms 72.12% of its industry peers.
Industry RankSector Rank
ROA -19.44%
ROE -34.14%
ROIC N/A
ROA(3y)-110.53%
ROA(5y)-101.93%
ROE(3y)-476.9%
ROE(5y)-372.11%
ROIC(3y)N/A
ROIC(5y)N/A
ABVC Yearly ROA, ROE, ROICABVC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K

1.3 Margins

  • ABVC's Gross Margin of 63.76% is fine compared to the rest of the industry. ABVC outperforms 79.23% of its industry peers.
  • ABVC's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ABVC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.89%
GM growth 5Y0.55%
ABVC Yearly Profit, Operating, Gross MarginsABVC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ABVC Health Analysis

2.1 Basic Checks

  • ABVC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ABVC has been increased compared to 1 year ago.
  • The number of shares outstanding for ABVC has been increased compared to 5 years ago.
  • ABVC has a worse debt/assets ratio than last year.
ABVC Yearly Shares OutstandingABVC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ABVC Yearly Total Debt VS Total AssetsABVC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -3.24, we must say that ABVC is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ABVC (-3.24) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.07 indicates that ABVC is not too dependend on debt financing.
  • ABVC's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. ABVC is outperformed by 60.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -3.24
ROIC/WACCN/A
WACC8.33%
ABVC Yearly LT Debt VS Equity VS FCFABVC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • ABVC has a Current Ratio of 0.63. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ABVC has a worse Current ratio (0.63) than 89.42% of its industry peers.
  • A Quick Ratio of 0.62 indicates that ABVC may have some problems paying its short term obligations.
  • ABVC has a worse Quick ratio (0.62) than 88.85% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.62
ABVC Yearly Current Assets VS Current LiabilitesABVC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ABVC Growth Analysis

3.1 Past

  • ABVC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.08%, which is quite impressive.
  • Looking at the last year, ABVC shows a very strong growth in Revenue. The Revenue has grown by 56.53%.
  • ABVC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.15% yearly.
EPS 1Y (TTM)77.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168%
Revenue 1Y (TTM)56.53%
Revenue growth 3Y12.28%
Revenue growth 5Y-6.15%
Sales Q2Q%104.47%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABVC Yearly Revenue VS EstimatesABVC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
ABVC Yearly EPS VS EstimatesABVC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. ABVC Valuation Analysis

4.1 Price/Earnings Ratio

  • ABVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ABVC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVC Price Earnings VS Forward Price EarningsABVC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVC Per share dataABVC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABVC Dividend Analysis

5.1 Amount

  • ABVC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABVC Fundamentals: All Metrics, Ratios and Statistics

ABVC BIOPHARMA INC

NASDAQ:ABVC (3/4/2026, 12:55:49 PM)

1.42

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)04-13
Inst Owners3.23%
Inst Owner Change9.03%
Ins Owners7.95%
Ins Owner Change0%
Market Cap36.64M
Revenue(TTM)798.00K
Net Income(TTM)-4.12M
Analysts43.33
Price TargetN/A
Short Float %1.08%
Short Ratio4.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45.91
P/FCF N/A
P/OCF N/A
P/B 3.04
P/tB 3.04
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.03
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.44%
ROE -34.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.76%
FCFM N/A
ROA(3y)-110.53%
ROA(5y)-101.93%
ROE(3y)-476.9%
ROE(5y)-372.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.89%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.62
Altman-Z -3.24
F-Score5
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)224.8%
Cap/Depr(5y)N/A
Cap/Sales(3y)8.76%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168%
EPS Next Y-4.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)56.53%
Revenue growth 3Y12.28%
Revenue growth 5Y-6.15%
Sales Q2Q%104.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.23%
OCF growth 3YN/A
OCF growth 5YN/A

ABVC BIOPHARMA INC / ABVC FAQ

What is the ChartMill fundamental rating of ABVC BIOPHARMA INC (ABVC) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ABVC.


Can you provide the valuation status for ABVC BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to ABVC BIOPHARMA INC (ABVC). This can be considered as Overvalued.


How profitable is ABVC BIOPHARMA INC (ABVC) stock?

ABVC BIOPHARMA INC (ABVC) has a profitability rating of 2 / 10.


What is the financial health of ABVC BIOPHARMA INC (ABVC) stock?

The financial health rating of ABVC BIOPHARMA INC (ABVC) is 1 / 10.